Cyclo Therapeutics, Inc. (CYTH) Stock Overview
Explore Cyclo Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Cyclo Therapeutics, Inc. (CYTH)
Key Financials
Key Financials
Market Cap
23.6M
P/E Ratio
-0.59
EPS (TTM)
$-0.90
ROE
-7.30%
CYTH Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Cyclo Therapeutics, Inc. (NASDAQ: CYTH) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Cyclo Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CYTH on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.
Key metrics behind Cyclo Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -0.59 and a market capitalization of 23.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CYTH on the NASDAQ.